(CercleFinance.com) – Innate Pharma announces the expiry of the waiting period provided for by US law, and therefore the entry into force of the agreement granting Sanofi an exclusive license for the multi-specific antibody program involving NK cells targeting B7H3.
Sanofi has also acquired an option to add up to two additional targets from Innate’s ANKET platform. Following the selection of each drug candidate, he will be responsible for the development, manufacture and marketing of the products.
Under the terms of the agreement, Innate will receive an upfront payment of 25 million euros and up to 1.35 billion euros in milestone payments linked to the achievement of objectives, as well as royalties on potential net sales.